Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Collaboration expense, net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

CRISPR Therapeutics

CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Its CRISPR/Cas9 platform is a gene editing technology that allows for precise, directed changes to genomic DNA. The firm offers a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan and Craig Mellow on October 31, 2013 and is headquartered in Zug, Switzerland.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Its CRISPR/Cas9 platform is a gene editing technology that allows for precise, directed changes to genomic DNA. The firm offers a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan, and Craig Mellow on October 31, 2013 and is headquartered in Zug, Switzerland.

UiPath

Block

As investors, we are always aiming to reevaluate our portfolios and make additions. However, we can often get lost in the vastness of the markets when deciding on just a handful of companies.

The 3 Best Cathie Wood Stocks to Buy in May 2024

Axsome Therapeutics

Iovance Biotherapeutics

The biotech sector holds some of the most promising and popular stocks on the market. With the promise of breakthrough treatments that generate billions of dollars annually, investors always look for the next up-and-comer.

The 3 Most Undervalued Biotech Stocks to Buy in May 2024

CRISPR Therapeutics (CRSP) reports mixed earnings results for first-quarter 2024. Management claims that the commercial launch for the first ever CRISPR-based gene therapy is progressing well.

CRISPR's (CRSP) Q1 Loss Narrower-Than-Expected, Sales Miss

ZUG, Switzerland and BOSTON, May 09, 2024 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team will present at the Bank of America Securities Health Care Conference on Wednesday, May 15, 2024, at 12:20 p.m. ET.

CRISPR Therapeutics to Present at the Bank of America Securities Health Care Conference

CRISPR Therapeutics AG (CRSP) came out with a quarterly loss of $1.43 per share versus the Zacks Consensus Estimate of a loss of $1.63. This compares to loss of $0.67 per share a year ago.

CRISPR Therapeutics AG (CRSP) Reports Q1 Loss, Misses Revenue Estimates

-More than 25 authorized treatment centers (ATCs) activated globally for CASGEVY™ and multiple patients have already had cells collected-

CRISPR Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results

- ASGCT presentation demonstrates lipid nanoparticle (LNP) mediated delivery to the eye in the context of editing of the myocilin (MYOC) gene as a potential treatment for glaucoma -

CRISPR Therapeutics Highlights ASGCT Oral Presentation and Announces New Programs Utilizing In Vivo Gene Editing Approach

Regeneron Pharmaceuticals

Sarepta Therapeutics

Biotechnology offers breakthrough drugs and treatments that open new doors in the field of medicine. Companies are releasing more drugs and developing state-of-the-art methods to treat previously untreatable conditions.

3 Biotech Stocks With the Potential to Make You an Overnight Millionaire

In the most recent trading session, CRISPR Therapeutics AG (CRSP) closed at $55.89, indicating a +1.49% shift from the previous trading day.

CRISPR Therapeutics AG (CRSP) Outperforms Broader Market: What You Need to Know

Intellia Therapeutics

Vertex Pharmaceuticals

Gene editing stocks are among the most intriguing in the biotech scene. The genomics revolution may be as exciting as the ongoing artificial intelligence one.

Shhh! 3 Secret Gene Editing Stocks Flying Below Wall Street's Radar

Crispr Therapeutics AG stock has plunged deep into a bear market. The FOMO attributed to Crispr's Casgevy approvals is likely dissipated. Crispr has an expanding early-stage portfolio. Crispr is also gaining traction to improve Casgevy's safety profile.

Crispr Therapeutics: Market Misunderstanding Is Your Buying Opportunity (Upgrade)

Sanofi

CRISPR Therapeutics, Regeneron, and Sanofi all deserve a close look now. These three biotechs have important growth drivers on the market.

3 Biotech Stocks to Buy and Hold Through 2030 and Beyond

Eli Lilly

Viking Therapeutics

While a weakening economy and a subsequent dip in the stock market are unfortunate, they are inevitabilities. Even booming segments like the biotech sector are not immune to the general trend of recessions that Western economies experienced over the last 40 years or so.

Stock Market Crash Alert: 3 Must-Buy Biotech Stocks When Prices Plunge

Recently, Zacks.com users have been paying close attention to CRISPR Therapeutics (CRSP). This makes it worthwhile to examine what the stock has in store.

Here is What to Know Beyond Why CRISPR Therapeutics AG (CRSP) is a Trending Stock

CRISPR/Cas9 technology allows for precise editing of DNA, potentially treating human diseases by replacing entire genes. CRISPR Therapeutics has developed the first FDA-approved ex vivo CRISPR/Cas9 therapy, Casgevy, for sickle cell disease and transfusion-dependent beta-thalassemia. The market seems pessimistic about the commercialization of these therapies, but if successful, CRISPR Therapeutics could generate significant shareholder value, perhaps nearly equal to the Enterprise Value of the company.

Invest In A Revolutionary Gene Therapy With CRISPR Therapeutics

Despite recent FDA approvals for its groundbreaking gene editing technology, CRISPR Therapeutics' stock has experienced a decline in value. The company's pipeline of treatments for various diseases presents a significant opportunity for future growth and market expansion. CRISPR Therapeutics has managed financial risks through partnerships and has enough cash on hand to fund operations for at least 24 months.

Crispr Therapeutics: Now Is The Time To Buy

ZUG, Switzerland and BOSTON, April 22, 2024 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced an oral presentation highlighting the Company's lipid nanoparticle (LNP) approach for ocular editing will be presented at the American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting, taking place May 7 – 11, 2024, in Baltimore, MD and virtually.

CRISPR Therapeutics to Present Oral Presentation at the American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting

Crispr Therapeutics AG (NASDAQ:CRSP) is 2.8% lower at $56.35 this afternoon, continuing a pullback from a Feb. 22, more than two-year high of $91.10.

Bullish Trendline Has Never Failed Crispr Therapeutics Stock

Is Trending Stock CRISPR Therapeutics AG (CRSP) a Buy Now?

CRISPR Therapeutics has significant upside potential. Eli Lilly could become an even bigger healthcare giant.

3 Magnificent Stocks That Could Double or More by 2030

AbbVie

Johnson & Johnson

Biotech stocks were among the worst performers in 2023. And so far in 2024, investors are still waiting on the recovery rally.

Wall Street Favorites: 3 Biotech Stocks With Strong Buy Ratings for April 2024

CRISPR Therapeutics AG (NASDAQ:CRSP ) Annual Needham Virtual Healthcare Conference Call April 10, 2024 11:45 AM ET Company Participants Samarth Kulkarni - Chief Executive Officer and Chairman Conference Call Participants Gil Blum - Needham & Company Gil Blum Good morning, everyone, and thank you for joining us on the Third Day of the Needham Healthcare Conference. My name is Gil Blum and I am a Senior Biotech Analyst with a focus on immune oncology.

CRISPR Therapeutics AG (CRSP) Annual Needham Virtual Healthcare Conference - (Transcript)

In the latest trading session, CRISPR Therapeutics AG (CRSP) closed at $65.19, marking a +1.72% move from the previous day.

CRISPR Therapeutics AG (CRSP) Exceeds Market Returns: Some Facts to Consider

CRISPR Therapeutics' newly approved product could turn out to be very lucrative. Viking Therapeutics' leading candidate is rightfully grabbing plenty of attention.

Better Buy: CRISPR Therapeutics Vs. Viking Therapeutics

Both of these companies recently won regulatory approval for their first products. Both Iovance Biotherapeutics and CRISPR Therapeutics have developed game-changing treatment technologies.

News for CRISPR Therapeutics Stock (CRSP)